Company intelligence / Profile preview

VFA Bio

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

VFA Bio is a preclinical-stage biotechnology company focused on developing novel therapeutics for inflammatory and autoimmune diseases. The company specializes in targeting the V-set and Immunoglobulin domain-containing (VSIG) family of proteins, which are critical regulators of the immune system. Their lead candidate, VFA-001, is a monoclonal antibody designed to act as a VSIG4 agonist to restore immune balance in conditions such as systemic lupus erythematosus and rheumatoid arthritis. VFA Bio's platform leverages deep biological insights into immune checkpoints to create first-in-class treatments for patients with chronic inflammatory disorders.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on VFA Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VFA Bio.

Explore the full profile